Lauder, Sarah N. http://orcid.org/0000-0003-2561-6277
Smart, Kathryn
Bart, Valentina M. T.
Pires, Ana
Scott, Jake
Milutinovic, Stefan
Godkin, Andrew
Vanhaesebroeck, Bart http://orcid.org/0000-0002-7074-3673
Gallimore, Awen
Funding for this research was provided by:
Wellcome Trust (209213/Z/17/Z)
Cancer Research UK (C23338/A25722, C16731/A21200)
Breast Cancer Now (PR1377)
Article History
Received: 29 October 2021
Revised: 28 June 2022
Accepted: 12 July 2022
First Online: 19 August 2022
Competing interests
: BV is a consultant for Olema Pharmaceuticals (San Francisco, USA), iOnctura (Geneva, Switzerland), Pharmingen (Leiden, the Netherlands), a shareholder in Open Orphan (London, UK) and has received speaker fees from Gilead (Foster City, USA). The remaining authors declare no competing interests relating to this work. The authors have no additional financial interests.
: Not applicable.
: Not applicable.